<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">91737</article-id><article-id pub-id-type="doi">10.7554/eLife.91737</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-217309"><name><surname>Chen</surname><given-names>Guanglei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-217312"><name><surname>Gu</surname><given-names>Xi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-330525"><name><surname>Xue</surname><given-names>Jinqi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-331532"><name><surname>Zhang</surname><given-names>Xu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-331533"><name><surname>Yu</surname><given-names>Xiaopeng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-331440"><name><surname>Zhang</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-330541"><name><surname>Li</surname><given-names>Ailin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-330527"><name><surname>Zhao</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-330547"><name><surname>He</surname><given-names>Guijin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-330529"><name><surname>Tang</surname><given-names>Meiyue</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-330542"><name><surname>Xing</surname><given-names>Fei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-331441"><name><surname>Yin</surname><given-names>Jianqiao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-331534"><name><surname>Bian</surname><given-names>Xiaobo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-316680"><name><surname>Han</surname><given-names>Ye</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2929-8122</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-330543"><name><surname>Cao</surname><given-names>Shuo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-330535"><name><surname>Liu</surname><given-names>Chao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-330536"><name><surname>Jiang</surname><given-names>Xiaofan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-331443"><name><surname>Zhang</surname><given-names>Keliang</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-331444"><name><surname>Xia</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-254350"><name><surname>Li</surname><given-names>Huajun</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-254347"><name><surname>Niu</surname><given-names>Nan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-156274"><name><surname>Liu</surname><given-names>Caigang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2083-235X</contrib-id><email>angel-s205@163.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf4"/></contrib><on-behalf-of>On behalf of the Northeastern Clinical Research Alliance of Oncology (NCRAO)</on-behalf-of><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d4f246</institution-id><institution>Department of Oncology, Shengjing Hospital of China Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d4f246</institution-id><institution>Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province</institution><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/008w1vb37</institution-id><institution>Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Yantai</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution>Liaoning Center for Drug Evaluation and Inspection</institution><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04ayvvz32</institution-id><institution>Jiangsu Hengrui Pharmaceuticals</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ji</surname><given-names>Yaoting</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/033vjfk17</institution-id><institution>Wuhan University</institution></institution-wrap><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Harper</surname><given-names>Diane M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>University of Michigan–Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>22</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e91737</elocation-id><history><date date-type="received" iso-8601-date="2023-08-08"><day>08</day><month>08</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-11-15"><day>15</day><month>11</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2023-08-17"><day>17</day><month>08</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.08.14.23294091"/></event></pub-history><permissions><copyright-statement>© 2023, Chen et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Chen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-91737-v1.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Emerging data have supported the immunostimulatory role of radiotherapy, which could exert a synergistic effect with immune checkpoint inhibitors (ICIs). With proven effective but suboptimal effect of ICI and chemotherapy in triple-negative breast cancer (TNBC), we designed a pilot study to explore the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT) plus adebrelimab and chemotherapy in TNBC patients.</p></sec><sec id="abs2"><title>Methods:</title><p>Treatment-naïve TNBC patients received two cycles of intravenous adebrelimab (20 mg/kg, every 3 weeks), and SBRT (24 Gy/3 f, every other day) started at the second cycle, then followed by six cycles of adebrelimab plus nab-paclitaxel (125 mg/m² on days 1 and 8) and carboplatin (area under the curve 6 mg/mL per min on day 1) every 3 weeks. The surgery was performed within 3–5 weeks after the end of neoadjuvant therapy. Primary endpoint was pathological complete response (pCR, ypT0/is ypN0). Secondary endpoints included objective response rate (ORR), residual cancer burden (RCB) 0-I, and safety.</p></sec><sec id="abs3"><title>Results:</title><p>13 patients were enrolled and received at least one dose of therapy. 10 (76.9%) patients completed SBRT and were included in efficacy analysis. 90% (9/10) of patients achieved pCR, both RCB 0-I and ORR reached 100% with three patients achieved complete remission. Adverse events (AEs) of all-grade and grade 3–4 occurred in 92.3% and 53.8%, respectively. One (7.7%) patient had treatment-related serious AEs. No radiation-related dermatitis or death occurred.</p></sec><sec id="abs4"><title>Conclusions:</title><p>Adding SBRT to adebrelimab and neoadjuvant chemotherapy led to a substantial proportion of pCR with acceptable toxicities, supporting further exploration of this combination in TNBC patients.</p></sec><sec id="abs5"><title>Funding:</title><p>None.</p></sec><sec id="abs6"><title>Clinical trial number:</title><p><related-object id="RO1" source-type="clinical-trials-registry" source-id="ClinicalTrials.gov" source-id-type="registry-name" document-id="NCT05132790" document-id-type="clinical-trial-number" xlink:href="https://clinicaltrials.gov/show/NCT05132790">NCT05132790</related-object>.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>breast cancer</kwd><kwd>immunotherapy</kwd><kwd>radiotherapy</kwd><kwd>neoadjuvant treatment</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><funding-statement>No external funding was received for this work.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Stereotactic body radiotherapy combined with immunotherapy and chemotherapy in neoadjuvant setting exhibited a promising anti-tumor activity and an acceptable safety profile in triple-negative breast cancer patients.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Triple-negative breast cancer (TNBC), defined as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) negative, accounts for approximately 10–20% of all breast cancers (<xref ref-type="bibr" rid="bib6">Costa et al., 2017</xref>). Characterized by higher tumor mutation burden and more intensive tumor-infiltrating lymphocytes infiltration in tumor microenvironment (TME) (<xref ref-type="bibr" rid="bib15">Loi et al., 2019</xref>), TNBC is more sensitive to immune checkpoint inhibitors (ICIs) than any other subtypes (<xref ref-type="bibr" rid="bib12">Keenan and Tolaney, 2020</xref>). Nowadays, the combination with pembrolizumab (a PD-1 blockade) and standard chemotherapy is recommended for TNBC patients with stages II–III according to National Comprehensive Cancer Network (NCCN) guidelines (<xref ref-type="bibr" rid="bib9">Gradishar et al., 2022</xref>). However, there is still around 40% of TNBC patients cannot achieve a pathological complete response (pCR) according to KEYNOTE-522 (<xref ref-type="bibr" rid="bib25">Schmid et al., 2020</xref>) and IMpassion031 (<xref ref-type="bibr" rid="bib18">Mittendorf et al., 2020</xref>) trials, which call for more promising strategies.</p><p>Radiotherapy (RT) is the most critical locoregional treatment in solid malignancies and approximately half of patients may receive radiotherapy during the entire treatment period (<xref ref-type="bibr" rid="bib2">Atun et al., 2015</xref>; <xref ref-type="bibr" rid="bib5">Citrin, 2017</xref>). Stereotactic body radiotherapy (SBRT), a novel technique with higher doses of radiation delivery to the tumor lesion in a smaller number of fractions, can shorten treatment time and reduce exposure to the surrounding tissues (<xref ref-type="bibr" rid="bib4">Chen et al., 2020</xref>). SBRT has already been widely applied to advanced breast cancer as salvage treatment targeting to osseous and brain metastasis or other oligometastatic sites (<xref ref-type="bibr" rid="bib19">Nicosia et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">Viani et al., 2021</xref>). Preoperative SBRT may be advantageous for downstaging the tumor to enable breast conservation and improving pCR rate (<xref ref-type="bibr" rid="bib23">Piras et al., 2023</xref>) and multiple trials investigating neoadjuvant SBRT in various malignancies (<xref ref-type="bibr" rid="bib11">Holyoake et al., 2021</xref>; <xref ref-type="bibr" rid="bib13">Kishi et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Liu et al., 2022</xref>; <xref ref-type="bibr" rid="bib20">Novikov et al., 2021</xref>) are currently ongoing. In addition, preclinical evidence suggested that SBRT has immunomodulatory properties by inducing cancer cells death to boost neoantigen-specific memory immune response and upregulate the expression of PD-L1 on tumor cells (<xref ref-type="bibr" rid="bib7">Deng et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Han et al., 2022</xref>; <xref ref-type="bibr" rid="bib21">Park et al., 2015</xref>). Given these, it would be promising to combine SBRT with ICIs and chemotherapy under the neoadjuvant setting.</p><p>Therefore, we conducted a prospective pilot study to determine the efficacy and safety of neoadjuvant SBRT in combination with adebrelimab (SHR-1316), a potent selective PD-L1 inhibitor, plus nab-paclitaxel and carboplatin in patients with newly diagnosed early or locally advanced TNBC, to validate the feasibility of this novel regimen in neoadjuvant treatment of TNBC.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Patients</title><p>Previously untreated patients aged between 18 and 75 years, with histologically confirmed invasive TNBC (defined as negative estrogen receptor, progesterone receptor, and HER2 status by American Society of Clinical Oncology/College of American Pathologists guidelines) and pathological tumor size ≥2.0 cm in MRI assessment, were eligible for enrollment. Other inclusion criteria included Eastern Cooperative Oncology Group performance score of 0–1, adequate marrow, hepatic, renal, and cardiac function.</p><p>Key exclusion criteria included bilateral, inflammatory, or occult breast cancer; active or a history of autoimmune disease; use of glucocorticoids or other immunosuppressive therapy within 2 weeks before the first study dose; a history of interstitial pneumonia; active tuberculosis; pregnancy, lactation, and refusal to use contraception.</p></sec><sec id="s2-2"><title>Study design and treatment</title><p>This study was performed in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines. The trial protocol and all amendments of this single-arm, prospective study was approved by the Institutional Review Board and Ethics Committee of Shengjing Hospital of China Medical University. Written informed consent was obtained from each patient before enrollment, and publish consents were obtained from all participated patients before submission.</p><p>All patients intravenously received 8 cycles of adebrelimab (20 mg/kg every 3 weeks). SBRT (24 Gy/3 f) targeted to breast lesion was started at the second cycle every other day, and 6 cycles of nab-paclitaxel (125 mg/m² on days 1 and 8) and carboplatin (area under the curve 6 mg/mL per min on day 1) was given every 3 weeks since the third cycle.</p><p>Patients who completed or discontinued the neoadjuvant treatment could undergo surgery. If disease progresses during the neoadjuvant phase, the patient either proceeds to surgery or receives alternative neoadjuvant therapy. Surgery was performed 3–5 weeks after the last dose of neoadjuvant therapy. Recommended surgery and adjuvant therapy were administered as per local guidelines or institutional standards.</p></sec><sec id="s2-3"><title>Outcomes</title><p>The primary endpoint was pCR rate in the breast and axillary lymph nodes (ypT0/is ypN0). Secondary endpoints included ORR before surgery (defined as the proportion of patients with complete or partial response according to the Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), the proportion of residual cancer burden (RCB) 0-I, and safety according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</p></sec><sec id="s2-4"><title>Statistical analysis</title><p>Efficacy was assessed in the modified intention-to-treat population, which included patients who had undergone radiotherapy. Safety was evaluated in all recruited patients who received at least one dose of study drug. All statistical analyses were conducted using SAS 9.4 (North Carolina, USA). Continuous data are presented as mean and standard deviation, or mean and 95% confidence interval (CI). Categorical data are expressed as frequency and percentage. The 95% CIs of pCR rate, proportion of patients with RCB 0-I, and ORR were estimated using the Clopper-Pearson method.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Patient characteristics</title><p>Between December 2021 and January 2023, 13 patients were recruited in the trial (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The baseline characteristics are shown in <xref ref-type="table" rid="table1">Table 1</xref>. The median age was 51 years (range 31–68) and the median tumor size was 33 mm (range, 22–72). Lymph node involvement was seen in 53.8% (7/13) patients and 46.2% (6/13) patients had stage III breast cancer at baseline.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Flowchart of the trial.</title><p>SBRT, stereotactic body radiotherapy.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91737-fig1-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Baseline characteristics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Characteristic</th><th align="left" valign="bottom">Patients (n=13)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Age (median, range</bold>)</td><td align="char" char="." valign="bottom">51 (31–68)</td></tr><tr><td align="left" valign="bottom"><bold>Age group, years</bold></td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom"> ≤50</td><td align="char" char="." valign="bottom">6 (46.2%)</td></tr><tr><td align="char" char="." valign="bottom"> &gt;50</td><td align="char" char="." valign="bottom">7 (53.8%)</td></tr><tr><td align="left" valign="bottom"><bold>Menopausal status</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Premenopausal</td><td align="char" char="." valign="bottom">6 (46.2%)</td></tr><tr><td align="left" valign="bottom"> Postmenopausal</td><td align="char" char="." valign="bottom">7 (53.8%)</td></tr><tr><td align="left" valign="bottom"><bold>Tumor size</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> T2</td><td align="char" char="." valign="bottom">10 (76.9%)</td></tr><tr><td align="left" valign="bottom"> T3</td><td align="char" char="." valign="bottom">3 (23.1%)</td></tr><tr><td align="left" valign="bottom"><bold>Lymph node status</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> N0</td><td align="char" char="." valign="bottom">6 (46.2%)</td></tr><tr><td align="left" valign="bottom"> N1</td><td align="char" char="." valign="bottom">2 (15.4%)</td></tr><tr><td align="left" valign="bottom"> N2</td><td align="char" char="." valign="bottom">5 (38.5%)</td></tr><tr><td align="left" valign="bottom"><bold>Clinical stage</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> IIA</td><td align="char" char="." valign="bottom">6 (46.2%)</td></tr><tr><td align="left" valign="bottom"> IIB</td><td align="char" char="." valign="bottom">1 (7.7%)</td></tr><tr><td align="left" valign="bottom"> IIIA</td><td align="char" char="." valign="bottom">6 (46.2%)</td></tr><tr><td align="left" valign="bottom"><bold>Tumor grade</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> II</td><td align="char" char="." valign="bottom">6 (46.2%)</td></tr><tr><td align="left" valign="bottom"> III</td><td align="char" char="." valign="bottom">5 (38.5%)</td></tr><tr><td align="left" valign="bottom"> Unknown</td><td align="char" char="." valign="bottom">2 (15.4%)</td></tr><tr><td align="left" valign="bottom"><bold>HER2 expression</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Negative</td><td align="char" char="." valign="bottom">8 (61.5%)</td></tr><tr><td align="char" char="." valign="bottom"> 1+</td><td align="char" char="." valign="bottom">3 (23.1%)</td></tr><tr><td align="char" char="." valign="bottom"> 2+, FISH-</td><td align="char" char="." valign="bottom">2 (15.4%)</td></tr></tbody></table></table-wrap></sec><sec id="s3-2"><title>Outcomes</title><p>Among the 13 treated patients, 2 (15.4%) were excluded after the first dose of adebrelimab due to protocol deviation and 1 (7.7%) discontinued after the second dose of adebrelimab due to adverse event (AE), thus only 10 (76.9%) who underwent neoadjuvant SBRT and surgery (the modified intention-to-treat population) were available for efficacy evaluation (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Nine of the 10 efficacy-evaluable patients (90%, 95% CI 55.5–99.8%) achieved pCR in the breast and axillary lymph nodes, and the rates of RCB 0-I was 100% (95% CI 67.9–100.0%). The radiological ORR was 100% (95% CI 67.9–100.0%, <xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig2">Figure 2</xref>) with three patients achieved complete radiographic response. Four patients with positive lymph node at baseline had nodal downstaging to N0 after neoadjuvant treatment.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Pathological and clinical response.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variable</th><th align="left" valign="bottom">Patients (n=10)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Total pathological complete response</bold></td><td align="char" char="." valign="bottom">9 (90%)</td></tr><tr><td align="left" valign="bottom"><bold>Residual cancer burden score</bold></td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom"> 0</td><td align="char" char="." valign="bottom">9 (90%)</td></tr><tr><td align="left" valign="bottom"> I</td><td align="char" char="." valign="bottom">1 (10%)</td></tr><tr><td align="left" valign="bottom"> II</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"> III</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><bold>Radiological response</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Complete response</td><td align="char" char="." valign="bottom">3 (30%)</td></tr><tr><td align="left" valign="bottom"> Partial response</td><td align="char" char="." valign="bottom">7 (70%)</td></tr><tr><td align="left" valign="bottom"> Stable disease</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"> Objective response rate</td><td align="char" char="." valign="bottom">10 (100%)</td></tr></tbody></table></table-wrap><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Swimming plot which demonstrates the pCR, RCB, and radiological response profile of 10 modified intention-to-treat population who received radiotherapy and undergone surgery.</title><p>Each round dot or column indicates a patient. Colors indicate different clinical stage. ID, identity; pCR, pathological complete response; RCB, residual cancer burden.</p><p><supplementary-material id="fig2scode1"><label>Figure 2—source code 1.</label><caption><title>R Code for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91737-fig2-code1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw information for the pCR, RCB, and radiological response profile of 10 modified intention-to-treat population who received radiotherapy and underwent surgery.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91737-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91737-fig2-v1.tif"/></fig></sec><sec id="s3-3"><title>Safety</title><p>AEs were reported in all 13 patients (<xref ref-type="table" rid="table3">Table 3</xref>). The incidence of any grade AEs was 92.3%. The grade 3 or higher treatment-related AEs occurred in 53.8% of the patients, including neutropenia (30.8%), anemia (7.7%), leukopenia (7.7%), thrombocytopenia (7.7%), creatine phosphokinase elevation (7.7%), and diarrhea (7.7%). Immune-related AEs of any grade occurred in 23.1% of the patients, including two (15.4%) patients had hyperthyroidism, one (7.7%) patient had hypothyroidism, and one (7.7%) patient experienced serious AEs due to immune-mediated myositis. Two patients required a dose reduction of carboplatin due to AEs but ultimately complete the prescribed treatment. There were no therapy-related death and no radiation-related dermatitis and skin hyperpigmentation.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Treatment-related adverse events.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom">Patients (n=13)</th><th align="left" valign="bottom"/></tr><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Grade 1 or 2</th><th align="left" valign="bottom">Grade 3</th><th align="left" valign="bottom">Grade 4</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Total</bold></td><td align="char" char="." valign="bottom">5 (38.5%)</td><td align="char" char="." valign="bottom">6 (46.2%)</td><td align="char" char="." valign="bottom">1 (7.7%)</td></tr><tr><td align="left" valign="bottom">Anemia</td><td align="char" char="." valign="bottom">8 (61.5%)</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Alopecia</td><td align="char" char="." valign="bottom">9 (69.2%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Neutropenia</td><td align="char" char="." valign="bottom">4 (30.8%)</td><td align="char" char="." valign="bottom">3 (23.1%)</td><td align="char" char="." valign="bottom">1 (7.7%)</td></tr><tr><td align="left" valign="bottom">Hyponatremia</td><td align="char" char="." valign="bottom">8 (61.5%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Nausea</td><td align="char" char="." valign="bottom">8 (61.5%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Leukopenia</td><td align="char" char="." valign="bottom">6 (46.2%)</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Lymphopenia</td><td align="char" char="." valign="bottom">7 (53.8%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Thrombocytopenia</td><td align="char" char="." valign="bottom">5 (38.5%)</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Elevated alanine aminotransferase level</td><td align="char" char="." valign="bottom">5 (38.5%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Elevated aspartate aminotransferase level</td><td align="char" char="." valign="bottom">5 (38.5%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Thyroid stimulating hormone decreased</td><td align="char" char="." valign="bottom">5 (38.5%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Hyperuricemia</td><td align="char" char="." valign="bottom">5 (38.5%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Vomiting</td><td align="char" char="." valign="bottom">5 (38.5%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Fatigue</td><td align="char" char="." valign="bottom">4 (30.8%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">γ-Glutamyl transferase increased</td><td align="char" char="." valign="bottom">3 (23.1%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Creatinine increased</td><td align="char" char="." valign="bottom">3 (23.1%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Thyroid stimulating hormone increased</td><td align="char" char="." valign="bottom">3 (23.1%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Creatine phosphokinase elevation</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Hyperthyroidism</td><td align="char" char="." valign="bottom">2 (15.4%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Free thyroid hormone decreased</td><td align="char" char="." valign="bottom">2 (15.4%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Hyperglycemia</td><td align="char" char="." valign="bottom">2 (15.4%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Hypokalemia</td><td align="char" char="." valign="bottom">2 (15.4%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Rash</td><td align="char" char="." valign="bottom">2 (15.4%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Peripheral neuropathy</td><td align="char" char="." valign="bottom">2 (15.4%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Diarrhea</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Immune mediated myositis</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Ventricular extrasystole</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Free thyroid hormone increased</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Hypothyroidism</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Troponin I elevated</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Proteinuria</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Constipation</td><td align="char" char="." valign="bottom">1 (7.7%)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td></tr></tbody></table></table-wrap></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>This pioneering study reported the efficacy and safety of neoadjuvant SBRT in combination with adebrelimab, nab-paclitaxel, and carboplatin in TNBC patients. This new therapeutic regimen achieved promising anti-tumor activity with pCR rate of 90%, and the RCB 0-I and ORR rate of 100%, respectively. More importantly, this combinatory therapeutic strategy was well tolerated in this population.</p><p>For TNBC patients who are candidates for preoperative therapy, neoadjuvant chemotherapy combined with ICIs has already achieved pCR rate of 58–64.8% in KEYNOTE-522 (<xref ref-type="bibr" rid="bib25">Schmid et al., 2020</xref>) and IMpassion031 study (<xref ref-type="bibr" rid="bib18">Mittendorf et al., 2020</xref>). In our study, the addition of SBRT to adebrelimab and standard neoadjuvant chemotherapy achieved a significantly higher percentage of pCR (90%). Since the dose of SBRT at 24 Gy in 3 fractions (bioequivalent dose=43.2 Gy) was lower than conventional preoperative radiotherapy dose (45–50 Gy/23–25 fractions) (<xref ref-type="bibr" rid="bib1">Ahmed et al., 2021</xref>), we thought that SBRT (24 Gy/3 f) alone could rarely achieve pCR. We speculated that the SBRT (24 Gy/3 f) may exert synergy with immunochemotherapy, and not just local tumor eradication effects.</p><p>Recently, SBRT has been preclinically identified as exerting immunomodulatory effects and synergizing anticancer immune responses combined with ICIs (<xref ref-type="bibr" rid="bib7">Deng et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Park et al., 2015</xref>). <xref ref-type="bibr" rid="bib22">Pilones et al., 2020</xref>, discovered that SBRT (two doses of 12 Gy) improved the therapeutic effects of PD-1 in a TNBC murine model, and this effect was enhanced by the addition of chemotherapy. TONIC trial demonstrated that SBRT (24 Gy/3 f) combined with nivolumab can increase the proportion of patients free of progression at 24 weeks than nivolumab alone (17% vs 8%) (<xref ref-type="bibr" rid="bib28">Voorwerk et al., 2019</xref>). Another small sample research has indicated that preoperative SBRT (19.5–31.5 Gy/3 f) with neoadjuvant chemotherapy may result in fair pCR rates of 36%, with the maximum response (pCR 67%) was obtained at a dose of 25.5 Gy/3 f (<xref ref-type="bibr" rid="bib3">Bondiau et al., 2013</xref>), as well as no increase in the incidences of early or late-term AEs (<xref ref-type="bibr" rid="bib23">Piras et al., 2023</xref>; <xref ref-type="bibr" rid="bib26">Takanen et al., 2022</xref>). Together, these studies suggested that SBRT may have strong immunomodulatory effects, rendering a synergistic anti-tumor effect with immunotherapy and chemotherapy.</p><p>Another study exploring SBRT (24 Gy/3 f) in combination with pembrolizumab plus chemotherapy in a neoadjuvant setting for TNBC patients also achieved a promising pCR rate of 74% (PEARL) (<xref ref-type="bibr" rid="bib16">McArthur et al., 2022</xref>). Noteworthy, PEARL study chose taxane-based chemotherapy in which 52% of patients received platinum, while our study used nab-paclitaxel and carboplatin-based regimens. It is well established that neoadjuvant chemotherapy containing platinum has shown an increase in pCR rates of approximately 15.1% in TNBC patients (<xref ref-type="bibr" rid="bib24">Poggio et al., 2018</xref>). Additionally, the IMpassion 130 (<xref ref-type="bibr" rid="bib8">Emens et al., 2021</xref>) and IMpassion 131 (<xref ref-type="bibr" rid="bib17">Miles et al., 2021</xref>) studies have suggested that nab-paclitaxel combined with ICIs may exhibit greater efficacy than paclitaxel. Thus, it is hypothesized that the selection of a chemotherapy regimen may contribute to the difference of pCR rates between the PEARL and our study (74% vs 90%). Consequently, it is imperative to determine the optimal neoadjuvant chemotherapy partners for ICIs in TNBC population.</p><p>AEs observed in our study were generally consistent with the known safety profiles of neoadjuvant therapy for TNBC patients in KEYNOTE-522 (<xref ref-type="bibr" rid="bib25">Schmid et al., 2020</xref>) and IMpassion031 (<xref ref-type="bibr" rid="bib18">Mittendorf et al., 2020</xref>) trials. The addition of SBRT did not increase any grades or grade 3 or above AEs, which were 92.3% vs 99% and 53.8% vs 57–76.8%, respectively. Furthermore, consistent with the customary toxic effects observed in lung cancers with adebrelimab plus carboplatin-based chemotherapy regimen (<xref ref-type="bibr" rid="bib29">Wang et al., 2022</xref>; <xref ref-type="bibr" rid="bib30">Yan et al., 2023</xref>), the addition of SBRT neither brought new AEs nor increased the incidences of grade 3 or higher or serious AEs in our population. Immune-related AEs occurred in three (23.1%) patients. The addition of SBRT did not increase immune-related AEs and severity compared to KEYNOTE-522.</p><p>Our study had several limitations including a non-comparative preliminary trial with relatively small sample size, thereby impeding the comparison of our data with historical data due to insufficient statistical power. Thus, further prospective randomized clinical trial required to validate these outcomes is currently in the planning stage.</p><p>In conclusion, the addition of SBRT to adebrelimab and neoadjuvant platinum-containing therapy showed the possibility of a convenient and feasible regimen for TNBC with promising efficacy and acceptable toxicities. Neoadjuvant radiotherapy may enhance the response to immunochemotherapy through activating TME. Further confirmation of these findings in large-scale study is currently underway.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Yan Xia is the employee of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other potential conflicts of interest were reported</p></fn><fn fn-type="COI-statement" id="conf3"><p>Huajun Li is the employee of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other potential conflicts of interest were reported</p></fn><fn fn-type="COI-statement" id="conf4"><p>Senior editor, eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Resources, Data curation, Software, Methodology</p></fn><fn fn-type="con" id="con2"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con5"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con6"><p>Software, Methodology</p></fn><fn fn-type="con" id="con7"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Resources</p></fn><fn fn-type="con" id="con10"><p>Resources</p></fn><fn fn-type="con" id="con11"><p>Resources</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Resources</p></fn><fn fn-type="con" id="con14"><p>Resources</p></fn><fn fn-type="con" id="con15"><p>Methodology</p></fn><fn fn-type="con" id="con16"><p>Software, Methodology</p></fn><fn fn-type="con" id="con17"><p>Writing - original draft</p></fn><fn fn-type="con" id="con18"><p>Investigation</p></fn><fn fn-type="con" id="con19"><p>Methodology</p></fn><fn fn-type="con" id="con20"><p>Methodology</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Methodology, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con22"><p>Conceptualization, Resources, Supervision, Validation, Investigation, Visualization, Methodology, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Clinical trial registration NCT05132790.</p></fn><fn fn-type="other"><p>Human subjects: The study was approved by Institutional Review Board of Shengjing Hospital, China Medical University and performed, according to the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from each patient.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-91737-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="repstand1"><label>Reporting standard 1.</label><caption><title>The STROBE checklist.</title></caption><media xlink:href="elife-91737-repstand1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The data are not publicly available due to privacy or ethical restrictions or laws and regulations, which are available from the principal investigator (<ext-link ext-link-type="uri" xlink:href="https://www.sj-hospital.org/english/">liucg@sj-hospital.org</ext-link>) on reasonable request. Qualified researchers should submit a proposal to the principal investigator outlining the reasons for requiring the data. The PI and IRB affiliated to Shenging Hospital will check whether the request is subject to any intellectual property or confidentiality obligations. De-identified data will then be transferred to the inquiring investigator over secure file transfer. Commercial use of this data must comply with the requirements of Human Genetics Resources Administration of China and other country, a signed data access agreement with the principal investigator is required before commercial research be performed. Source data files have been provided for Figure 2. The code that was used to analyze the data has already been provided, shown in word document (Figure 2 - source data 1).</p></sec><ack id="ack"><title>Acknowledgements</title><p>Jiangsu Hengrui Pharmaceuticals Co, Ltd provided the study drug adebrelimab free of charge for patients enrolled in the study. We thank the patients and their families involved in this study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Jozsa</surname><given-names>F</given-names></name><name><surname>Douek</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A systematic review of neo-adjuvant radiotherapy in the treatment of breast cancer</article-title><source>Ecancermedicalscience</source><volume>15</volume><elocation-id>1175</elocation-id><pub-id pub-id-type="doi">10.3332/ecancer.2021.1175</pub-id><pub-id pub-id-type="pmid">33680089</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atun</surname><given-names>R</given-names></name><name><surname>Jaffray</surname><given-names>DA</given-names></name><name><surname>Barton</surname><given-names>MB</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Baumann</surname><given-names>M</given-names></name><name><surname>Vikram</surname><given-names>B</given-names></name><name><surname>Hanna</surname><given-names>TP</given-names></name><name><surname>Knaul</surname><given-names>FM</given-names></name><name><surname>Lievens</surname><given-names>Y</given-names></name><name><surname>Lui</surname><given-names>TYM</given-names></name><name><surname>Milosevic</surname><given-names>M</given-names></name><name><surname>O’Sullivan</surname><given-names>B</given-names></name><name><surname>Rodin</surname><given-names>DL</given-names></name><name><surname>Rosenblatt</surname><given-names>E</given-names></name><name><surname>Van Dyk</surname><given-names>J</given-names></name><name><surname>Yap</surname><given-names>ML</given-names></name><name><surname>Zubizarreta</surname><given-names>E</given-names></name><name><surname>Gospodarowicz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Expanding global access to radiotherapy</article-title><source>The Lancet. Oncology</source><volume>16</volume><fpage>1153</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00222-3</pub-id><pub-id pub-id-type="pmid">26419354</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bondiau</surname><given-names>PY</given-names></name><name><surname>Courdi</surname><given-names>A</given-names></name><name><surname>Bahadoran</surname><given-names>P</given-names></name><name><surname>Chamorey</surname><given-names>E</given-names></name><name><surname>Queille-Roussel</surname><given-names>C</given-names></name><name><surname>Lallement</surname><given-names>M</given-names></name><name><surname>Birtwisle-Peyrottes</surname><given-names>I</given-names></name><name><surname>Chapellier</surname><given-names>C</given-names></name><name><surname>Pacquelet-Cheli</surname><given-names>S</given-names></name><name><surname>Ferrero</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer</article-title><source>International Journal of Radiation Oncology, Biology, Physics</source><volume>85</volume><fpage>1193</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2012.10.034</pub-id><pub-id pub-id-type="pmid">23332384</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges</article-title><source>Journal of Hematology &amp; Oncology</source><volume>13</volume><elocation-id>105</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-020-00940-z</pub-id><pub-id pub-id-type="pmid">32723363</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citrin</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Recent Developments in Radiotherapy</article-title><source>The New England Journal of Medicine</source><volume>377</volume><fpage>2200</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1713349</pub-id><pub-id pub-id-type="pmid">29171815</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>R</given-names></name><name><surname>Shah</surname><given-names>AN</given-names></name><name><surname>Santa-Maria</surname><given-names>CA</given-names></name><name><surname>Cruz</surname><given-names>MR</given-names></name><name><surname>Mahalingam</surname><given-names>D</given-names></name><name><surname>Carneiro</surname><given-names>BA</given-names></name><name><surname>Chae</surname><given-names>YK</given-names></name><name><surname>Cristofanilli</surname><given-names>M</given-names></name><name><surname>Gradishar</surname><given-names>WJ</given-names></name><name><surname>Giles</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development</article-title><source>Cancer Treatment Reviews</source><volume>53</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2016.12.010</pub-id><pub-id pub-id-type="pmid">28104566</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Burnette</surname><given-names>B</given-names></name><name><surname>Beckett</surname><given-names>M</given-names></name><name><surname>Darga</surname><given-names>T</given-names></name><name><surname>Weichselbaum</surname><given-names>RR</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice</article-title><source>The Journal of Clinical Investigation</source><volume>124</volume><fpage>687</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1172/JCI67313</pub-id><pub-id pub-id-type="pmid">24382348</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emens</surname><given-names>LA</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><name><surname>Diéras</surname><given-names>V</given-names></name><name><surname>Iwata</surname><given-names>H</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Schneeweiss</surname><given-names>A</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Henschel</surname><given-names>V</given-names></name><name><surname>Swat</surname><given-names>A</given-names></name><name><surname>Kaul</surname><given-names>M</given-names></name><name><surname>Molinero</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Chui</surname><given-names>SY</given-names></name><name><surname>Schmid</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Corrigendum to “First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis”: Annals of Oncology 2021; 32: 983-993</article-title><source>Annals of Oncology</source><volume>32</volume><elocation-id>1650</elocation-id><pub-id pub-id-type="doi">10.1016/j.annonc.2021.10.002</pub-id><pub-id pub-id-type="pmid">34740469</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gradishar</surname><given-names>WJ</given-names></name><name><surname>Moran</surname><given-names>MS</given-names></name><name><surname>Abraham</surname><given-names>J</given-names></name><name><surname>Aft</surname><given-names>R</given-names></name><name><surname>Agnese</surname><given-names>D</given-names></name><name><surname>Allison</surname><given-names>KH</given-names></name><name><surname>Anderson</surname><given-names>B</given-names></name><name><surname>Burstein</surname><given-names>HJ</given-names></name><name><surname>Chew</surname><given-names>H</given-names></name><name><surname>Dang</surname><given-names>C</given-names></name><name><surname>Elias</surname><given-names>AD</given-names></name><name><surname>Giordano</surname><given-names>SH</given-names></name><name><surname>Goetz</surname><given-names>MP</given-names></name><name><surname>Goldstein</surname><given-names>LJ</given-names></name><name><surname>Hurvitz</surname><given-names>SA</given-names></name><name><surname>Isakoff</surname><given-names>SJ</given-names></name><name><surname>Jankowitz</surname><given-names>RC</given-names></name><name><surname>Javid</surname><given-names>SH</given-names></name><name><surname>Krishnamurthy</surname><given-names>J</given-names></name><name><surname>Leitch</surname><given-names>M</given-names></name><name><surname>Lyons</surname><given-names>J</given-names></name><name><surname>Mortimer</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>SA</given-names></name><name><surname>Pierce</surname><given-names>LJ</given-names></name><name><surname>Rosenberger</surname><given-names>LH</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Sitapati</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>KL</given-names></name><name><surname>Smith</surname><given-names>ML</given-names></name><name><surname>Soliman</surname><given-names>H</given-names></name><name><surname>Stringer-Reasor</surname><given-names>EM</given-names></name><name><surname>Telli</surname><given-names>ML</given-names></name><name><surname>Ward</surname><given-names>JH</given-names></name><name><surname>Wisinski</surname><given-names>KB</given-names></name><name><surname>Young</surname><given-names>JS</given-names></name><name><surname>Burns</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology</article-title><source>Journal of the National Comprehensive Cancer Network</source><volume>20</volume><fpage>691</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2022.0030</pub-id><pub-id pub-id-type="pmid">35714673</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>MG</given-names></name><name><surname>Wee</surname><given-names>CW</given-names></name><name><surname>Kang</surname><given-names>MH</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Jeon</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model</article-title><source>Cancers</source><volume>14</volume><elocation-id>2692</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14112692</pub-id><pub-id pub-id-type="pmid">35681672</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holyoake</surname><given-names>DLP</given-names></name><name><surname>Robinson</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Grose</surname><given-names>D</given-names></name><name><surname>McIntosh</surname><given-names>D</given-names></name><name><surname>Sebag-Montefiore</surname><given-names>D</given-names></name><name><surname>Radhakrishna</surname><given-names>G</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Hawkins</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer</article-title><source>Radiotherapy and Oncology</source><volume>155</volume><fpage>278</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2020.11.007</pub-id><pub-id pub-id-type="pmid">33217498</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>TE</given-names></name><name><surname>Tolaney</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Role of Immunotherapy in Triple-Negative Breast Cancer</article-title><source>Journal of the National Comprehensive Cancer Network</source><volume>18</volume><fpage>479</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2020.7554</pub-id><pub-id pub-id-type="pmid">32259782</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname><given-names>N</given-names></name><name><surname>Kanayama</surname><given-names>N</given-names></name><name><surname>Hirata</surname><given-names>T</given-names></name><name><surname>Ohira</surname><given-names>S</given-names></name><name><surname>Wada</surname><given-names>K</given-names></name><name><surname>Kawaguchi</surname><given-names>Y</given-names></name><name><surname>Konishi</surname><given-names>K</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name><name><surname>Nakatsuka</surname><given-names>SI</given-names></name><name><surname>Marubashi</surname><given-names>S</given-names></name><name><surname>Tomokuni</surname><given-names>A</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Tomita</surname><given-names>Y</given-names></name><name><surname>Teshima</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Preoperative Stereotactic Body Radiotherapy to Portal Vein Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>4105</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-60871-0</pub-id><pub-id pub-id-type="pmid">32139751</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Veale</surname><given-names>C</given-names></name><name><surname>Hablitz</surname><given-names>D</given-names></name><name><surname>Krontiras</surname><given-names>H</given-names></name><name><surname>Dalton</surname><given-names>A</given-names></name><name><surname>Meyers</surname><given-names>K</given-names></name><name><surname>Dobelbower</surname><given-names>M</given-names></name><name><surname>Lancaster</surname><given-names>R</given-names></name><name><surname>Bredel</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>C</given-names></name><name><surname>Keene</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>E</given-names></name><name><surname>Boggs</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Feasibility and Short-Term Toxicity of a Consecutively Delivered Five Fraction Stereotactic Body Radiation Therapy Regimen in Early-Stage Breast Cancer Patients Receiving Partial Breast Irradiation</article-title><source>Frontiers in Oncology</source><volume>12</volume><elocation-id>901312</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2022.901312</pub-id><pub-id pub-id-type="pmid">35880164</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Drubay</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Pruneri</surname><given-names>G</given-names></name><name><surname>Francis</surname><given-names>PA</given-names></name><name><surname>Lacroix-Triki</surname><given-names>M</given-names></name><name><surname>Joensuu</surname><given-names>H</given-names></name><name><surname>Dieci</surname><given-names>MV</given-names></name><name><surname>Badve</surname><given-names>S</given-names></name><name><surname>Demaria</surname><given-names>S</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>Munzone</surname><given-names>E</given-names></name><name><surname>Lemonnier</surname><given-names>J</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Piccart</surname><given-names>MJ</given-names></name><name><surname>Kellokumpu-Lehtinen</surname><given-names>PL</given-names></name><name><surname>Vingiani</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Andre</surname><given-names>F</given-names></name><name><surname>Denkert</surname><given-names>C</given-names></name><name><surname>Salgado</surname><given-names>R</given-names></name><name><surname>Michiels</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers</article-title><source>Journal of Clinical Oncology</source><volume>37</volume><fpage>559</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.01010</pub-id><pub-id pub-id-type="pmid">30650045</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McArthur</surname><given-names>HL</given-names></name><name><surname>Shiao</surname><given-names>S</given-names></name><name><surname>Karlan</surname><given-names>S</given-names></name><name><surname>Basho</surname><given-names>R</given-names></name><name><surname>Amersi</surname><given-names>F</given-names></name><name><surname>Burnison</surname><given-names>M</given-names></name><name><surname>Mirhadi</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>CT</given-names></name><name><surname>Dang</surname><given-names>C</given-names></name><name><surname>Richardson</surname><given-names>H</given-names></name><name><surname>Giuliano</surname><given-names>AE</given-names></name><name><surname>Kapoor</surname><given-names>N</given-names></name><name><surname>Larkin</surname><given-names>B</given-names></name><name><surname>Godinez</surname><given-names>H</given-names></name><name><surname>Dunn</surname><given-names>SA</given-names></name><name><surname>Khameneh</surname><given-names>NH</given-names></name><name><surname>Knott</surname><given-names>S</given-names></name><name><surname>McAndrew</surname><given-names>P</given-names></name><name><surname>Mita</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>DJ</given-names></name><name><surname>Abaya</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Ly</surname><given-names>A</given-names></name><name><surname>Bossuyt</surname><given-names>V</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Abstract PD10-01: The PEARL trial: Pre-operative pembrolizumab with radiation therapy in early stage triple negative breast cancer</article-title><source>Cancer Research</source><volume>82</volume><elocation-id>D10-01</elocation-id><pub-id pub-id-type="doi">10.1158/1538-7445.SABCS21-PD10-01</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>D</given-names></name><name><surname>Gligorov</surname><given-names>J</given-names></name><name><surname>André</surname><given-names>F</given-names></name><name><surname>Cameron</surname><given-names>D</given-names></name><name><surname>Schneeweiss</surname><given-names>A</given-names></name><name><surname>Barrios</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Wardley</surname><given-names>A</given-names></name><name><surname>Kaen</surname><given-names>D</given-names></name><name><surname>Andrade</surname><given-names>L</given-names></name><name><surname>Semiglazov</surname><given-names>V</given-names></name><name><surname>Reinisch</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Patre</surname><given-names>M</given-names></name><name><surname>Morales</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>SL</given-names></name><name><surname>Kaul</surname><given-names>M</given-names></name><name><surname>Barata</surname><given-names>T</given-names></name><name><surname>O’Shaughnessy</surname><given-names>J</given-names></name><collab>IMpassion131 investigators</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer</article-title><source>Annals of Oncology</source><volume>32</volume><fpage>994</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.05.801</pub-id><pub-id pub-id-type="pmid">34219000</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittendorf</surname><given-names>EA</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><name><surname>Saji</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>KH</given-names></name><name><surname>Hegg</surname><given-names>R</given-names></name><name><surname>Koehler</surname><given-names>A</given-names></name><name><surname>Sohn</surname><given-names>J</given-names></name><name><surname>Iwata</surname><given-names>H</given-names></name><name><surname>Telli</surname><given-names>ML</given-names></name><name><surname>Ferrario</surname><given-names>C</given-names></name><name><surname>Punie</surname><given-names>K</given-names></name><name><surname>Penault-Llorca</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Duc</surname><given-names>AN</given-names></name><name><surname>Liste-Hermoso</surname><given-names>M</given-names></name><name><surname>Maiya</surname><given-names>V</given-names></name><name><surname>Molinero</surname><given-names>L</given-names></name><name><surname>Chui</surname><given-names>SY</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial</article-title><source>Lancet</source><volume>396</volume><fpage>1090</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31953-X</pub-id><pub-id pub-id-type="pmid">32966830</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicosia</surname><given-names>L</given-names></name><name><surname>Figlia</surname><given-names>V</given-names></name><name><surname>Ricottone</surname><given-names>N</given-names></name><name><surname>Cuccia</surname><given-names>F</given-names></name><name><surname>Mazzola</surname><given-names>R</given-names></name><name><surname>Giaj-Levra</surname><given-names>N</given-names></name><name><surname>Ricchetti</surname><given-names>F</given-names></name><name><surname>Rigo</surname><given-names>M</given-names></name><name><surname>Jafari</surname><given-names>F</given-names></name><name><surname>Maria Magrini</surname><given-names>S</given-names></name><name><surname>Girlando</surname><given-names>A</given-names></name><name><surname>Alongi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients</article-title><source>Clinical &amp; Experimental Metastasis</source><volume>39</volume><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1007/s10585-022-10167-6</pub-id><pub-id pub-id-type="pmid">35511313</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novikov</surname><given-names>SN</given-names></name><name><surname>Gafton</surname><given-names>GI</given-names></name><name><surname>Ebert</surname><given-names>MA</given-names></name><name><surname>Fedosova</surname><given-names>EA</given-names></name><name><surname>Melnik</surname><given-names>JS</given-names></name><name><surname>Zinovev</surname><given-names>GV</given-names></name><name><surname>Gafton</surname><given-names>IG</given-names></name><name><surname>Sinyachkin</surname><given-names>MS</given-names></name><name><surname>Kanaev</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Preoperative stereotactic ablative body radiotherapy with postoperative conventional irradiation of soft tissue sarcomas: Protocol overview with a preliminary safety report</article-title><source>Radiotherapy and Oncology</source><volume>161</volume><fpage>126</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2021.05.025</pub-id><pub-id pub-id-type="pmid">34089751</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SS</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Harrington</surname><given-names>SM</given-names></name><name><surname>Krco</surname><given-names>CJ</given-names></name><name><surname>Grams</surname><given-names>MP</given-names></name><name><surname>Mansfield</surname><given-names>AS</given-names></name><name><surname>Furutani</surname><given-names>KM</given-names></name><name><surname>Olivier</surname><given-names>KR</given-names></name><name><surname>Kwon</surname><given-names>ED</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PD-1 Restrains Radiotherapy-Induced Abscopal Effect</article-title><source>Cancer Immunology Research</source><volume>3</volume><fpage>610</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0138</pub-id><pub-id pub-id-type="pmid">25701325</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilones</surname><given-names>KA</given-names></name><name><surname>Hensler</surname><given-names>M</given-names></name><name><surname>Daviaud</surname><given-names>C</given-names></name><name><surname>Kraynak</surname><given-names>J</given-names></name><name><surname>Fucikova</surname><given-names>J</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Demaria</surname><given-names>S</given-names></name><name><surname>Formenti</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade</article-title><source>Oncoimmunology</source><volume>9</volume><elocation-id>1830524</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2020.1830524</pub-id><pub-id pub-id-type="pmid">33150045</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piras</surname><given-names>A</given-names></name><name><surname>Sanfratello</surname><given-names>A</given-names></name><name><surname>Boldrini</surname><given-names>L</given-names></name><name><surname>D’Aviero</surname><given-names>A</given-names></name><name><surname>Pernice</surname><given-names>G</given-names></name><name><surname>Sortino</surname><given-names>G</given-names></name><name><surname>Valerio</surname><given-names>MR</given-names></name><name><surname>Gennari</surname><given-names>R</given-names></name><name><surname>D’Angelo</surname><given-names>I</given-names></name><name><surname>Marazzi</surname><given-names>F</given-names></name><name><surname>Angileri</surname><given-names>T</given-names></name><name><surname>Daidone</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Stereotactic radiotherapy in early-stage breast cancer in neoadjuvant and exclusive settings: a systematic review</article-title><source>Oncology Research and Treatment</source><volume>46</volume><fpage>116</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1159/000528640</pub-id><pub-id pub-id-type="pmid">36509043</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poggio</surname><given-names>F</given-names></name><name><surname>Bruzzone</surname><given-names>M</given-names></name><name><surname>Ceppi</surname><given-names>M</given-names></name><name><surname>Pondé</surname><given-names>NF</given-names></name><name><surname>La Valle</surname><given-names>G</given-names></name><name><surname>Del Mastro</surname><given-names>L</given-names></name><name><surname>de Azambuja</surname><given-names>E</given-names></name><name><surname>Lambertini</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis</article-title><source>Annals of Oncology</source><volume>29</volume><fpage>1497</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy127</pub-id><pub-id pub-id-type="pmid">29873695</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>P</given-names></name><name><surname>Dent</surname><given-names>R</given-names></name><name><surname>O’Shaughnessy</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pembrolizumab for Early Triple-Negative Breast Cancer. Reply</article-title><source>The New England Journal of Medicine</source><volume>382</volume><elocation-id>e108</elocation-id><pub-id pub-id-type="doi">10.1056/NEJMc2006684</pub-id><pub-id pub-id-type="pmid">32579835</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takanen</surname><given-names>S</given-names></name><name><surname>Pinnarò</surname><given-names>P</given-names></name><name><surname>Farina</surname><given-names>I</given-names></name><name><surname>Sperati</surname><given-names>F</given-names></name><name><surname>Botti</surname><given-names>C</given-names></name><name><surname>Vici</surname><given-names>P</given-names></name><name><surname>Soriani</surname><given-names>A</given-names></name><name><surname>Marucci</surname><given-names>L</given-names></name><name><surname>Sanguineti</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Stereotactic partial breast irradiation in primary breast cancer: A comprehensive review of the current status and future directions</article-title><source>Frontiers in Oncology</source><volume>12</volume><elocation-id>953810</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2022.953810</pub-id><pub-id pub-id-type="pmid">36313648</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viani</surname><given-names>GA</given-names></name><name><surname>Gouveia</surname><given-names>AG</given-names></name><name><surname>Louie</surname><given-names>AV</given-names></name><name><surname>Korzeniowski</surname><given-names>M</given-names></name><name><surname>Pavoni</surname><given-names>JF</given-names></name><name><surname>Hamamura</surname><given-names>AC</given-names></name><name><surname>Moraes</surname><given-names>FY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis</article-title><source>Radiotherapy and Oncology</source><volume>164</volume><fpage>245</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2021.09.031</pub-id><pub-id pub-id-type="pmid">34624408</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voorwerk</surname><given-names>L</given-names></name><name><surname>Slagter</surname><given-names>M</given-names></name><name><surname>Horlings</surname><given-names>HM</given-names></name><name><surname>Sikorska</surname><given-names>K</given-names></name><name><surname>van de Vijver</surname><given-names>KK</given-names></name><name><surname>de Maaker</surname><given-names>M</given-names></name><name><surname>Nederlof</surname><given-names>I</given-names></name><name><surname>Kluin</surname><given-names>RJC</given-names></name><name><surname>Warren</surname><given-names>S</given-names></name><name><surname>Ong</surname><given-names>S</given-names></name><name><surname>Wiersma</surname><given-names>TG</given-names></name><name><surname>Russell</surname><given-names>NS</given-names></name><name><surname>Lalezari</surname><given-names>F</given-names></name><name><surname>Schouten</surname><given-names>PC</given-names></name><name><surname>Bakker</surname><given-names>NAM</given-names></name><name><surname>Ketelaars</surname><given-names>SLC</given-names></name><name><surname>Peters</surname><given-names>D</given-names></name><name><surname>Lange</surname><given-names>CAH</given-names></name><name><surname>van Werkhoven</surname><given-names>E</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Mandjes</surname><given-names>IAM</given-names></name><name><surname>Kemper</surname><given-names>I</given-names></name><name><surname>Onderwater</surname><given-names>S</given-names></name><name><surname>Chalabi</surname><given-names>M</given-names></name><name><surname>Wilgenhof</surname><given-names>S</given-names></name><name><surname>Haanen</surname><given-names>J</given-names></name><name><surname>Salgado</surname><given-names>R</given-names></name><name><surname>de Visser</surname><given-names>KE</given-names></name><name><surname>Sonke</surname><given-names>GS</given-names></name><name><surname>Wessels</surname><given-names>LFA</given-names></name><name><surname>Linn</surname><given-names>SC</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Blank</surname><given-names>CU</given-names></name><name><surname>Kok</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial</article-title><source>Nature Medicine</source><volume>25</volume><elocation-id>1175</elocation-id><pub-id pub-id-type="doi">10.1038/s41591-019-0520-5</pub-id><pub-id pub-id-type="pmid">31209337</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Min</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><collab>CAPSTONE-1 Study Group</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>The Lancet. Oncology</source><volume>23</volume><fpage>739</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00224-8</pub-id><pub-id pub-id-type="pmid">35576956</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Zhong</surname><given-names>WZ</given-names></name><name><surname>Liu</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Xing</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Ge</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial</article-title><source>Journal of Thoracic Oncology</source><volume>18</volume><fpage>194</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2022.09.222</pub-id><pub-id pub-id-type="pmid">36191882</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91737.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ji</surname><given-names>Yaoting</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/033vjfk17</institution-id><institution>Wuhan University</institution></institution-wrap><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2023.08.14.23294091" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2023.08.14.23294091"/></front-stub><body><p>This study presents a valuable finding of a novel combinatory regimen that integrates immunotherapy, radiotherapy, and chemotherapy in the current refractory triple-negative breast cancer. The evidence supporting the claims of the authors is solid, although inclusion of a larger number of patient samples and an animal model would have strengthened the study. The work will be of interest to Clinicians working on breast cancer.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91737.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ji</surname><given-names>Yaoting</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/033vjfk17</institution-id><institution>Wuhan University</institution></institution-wrap><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Ji</surname><given-names>Yaoting</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/033vjfk17</institution-id><institution>Wuhan University</institution></institution-wrap><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Liu</surname><given-names>Jieqiong</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>Sun Yat-sen University</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Wang</surname><given-names>Xin</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02drdmm93</institution-id><institution>Chinese Academy of Medical Sciences &amp; Peking Union Medical College</institution></institution-wrap><country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2023.08.14.23294091">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2023.08.14.23294091v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Efficacy and Safety of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study&quot; for consideration by eLife. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Mone Zaidi as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. This study investigated a novel neoadjuvant regimen in early triple negative breast cancer, and the primary endpoint was selected as the pCR rate. While overall survival is the golden parameter for evaluating cancer-related survival, and whether the improvement of pCR rate in this study could predict the long-term survival benefit should be addressed.</p><p>2. This clinical trial explored the efficacy and safety of neoadjuvant radiotherapy combined with immunotherapy and chemotherapy in early stage triple negative breast cancer. Please add the adverse effects of radiotherapy.</p><p>3. It will be better to modify the language by the English native speaker.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. This work has innovatively and comprehensively demonstrated the efficacy and safety of immunotherapy which blocks PD-L1, combined with SBRT and chemotherapy in previous refractory triple-negative breast cancers. As side effects arise from SBRT and chemotherapy are commonly reported, whether the adverse events in this research are associated with specific immunotherapy should be explained, and strategies to deal with these AEs should be mentioned in the Discussion section.</p><p>2. The proper administration sequence of PD-L1 immunotherapy and radiotherapy should be supplemented, whether concurrent administration or sequential application of immunotherapy and radiotherapy could achieve better efficacy should be described.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. Immunotherapy + chemotherapy is the standard treatment recommended by current guidelines for high-risk triple-negative breast cancer. In this study, radiation therapy was administered to the primary breast lesion, and radiation therapy can cause an abscopal effect, so it is recommended to supplement the regression of lymph nodes in the node positive patients after radiation therapy and at the time of surgery.</p><p>2. The relatively small sample size of this study is the major defect of this study, and further confirmatory studies are still needed.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91737.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions</p><p>Reviewer #1 (Recommendations for the authors):</p><p>1. This study investigated a novel neoadjuvant regimen in early triple negative breast cancer, and the primary endpoint was selected as the pCR rate. While overall survival is the golden parameter for evaluating cancer-related survival, and whether the improvement of pCR rate in this study could predict the long-term survival benefit should be addressed.</p></disp-quote><p>It is really true as Reviewer#1 suggested that overall survival is the golden parameter. However, a pooled analysis of 12 neoadjuvant chemotherapy breast cancer clinical trials found that patients with breast cancer who achieved a pCR had significantly improved survival outcomes, and the association between pCR rates and long-term outcomes was strongest in patients with triple-negative breast cancer (OS: 0·16, 0·11–0·25). Considering that pCR rate is a surrogate endpoint for OS, we will continue to follow-up the patients and report the updated survival data.</p><p>References:</p><p>Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014</p><disp-quote content-type="editor-comment"><p>2. This clinical trial explored the efficacy and safety of neoadjuvant radiotherapy combined with immunotherapy and chemotherapy in early stage triple negative breast cancer. Please add the adverse effects of radiotherapy.</p></disp-quote><p>Thank you for your good suggestion. The adverse effects of radiotherapy were added both on Abstract (page 2, line 42) and Results section (page 8, line 154-155).</p><p>a) Abstract (page 2, line 42): No radiation-related dermatitis or death occurred.</p><p>b) Results section (page 8, line 154-155): There were no therapy-related death and no radiation-related dermatitis and skin hyperpigmentation.</p><disp-quote content-type="editor-comment"><p>3. It will be better to modify the language by the English native speaker.</p></disp-quote><p>We have polished the manuscript according to the Reviewer’s comments.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. This work has innovatively and comprehensively demonstrated the efficacy and safety of immunotherapy which blocks PD-L1, combined with SBRT and chemotherapy in previous refractory triple-negative breast cancers. As side effects arise from SBRT and chemotherapy are commonly reported, whether the adverse events in this research are associated with specific immunotherapy should be explained, and strategies to deal with these AEs should be mentioned in the Discussion section.</p></disp-quote><p>We have made amendments according to the Reviewer#2’s comments. The adverse effects of immunotherapy were added in Results section (page 8, line 151-152) and Discussion section (page 11, line 204-205).</p><p>a) Results section (page 8, line 151-152): Immune-related adverse events of any grade occurred in 23.1% of the patients, including 2 (15.4%) patients had hyperthyroidism, 1 (7.7%) patient had hypothyroidism, and 1 (7.7%) patient experienced serious adverse events due to immune-mediated myositis.</p><p>b) Discussion section (page 11, line 204-205): Immune-related adverse events occurred in 3 (23.1%) patients. The addition of SBRT did not increase immune-related adverse events and severity compared to KEYNOTE-522.</p><disp-quote content-type="editor-comment"><p>2. The proper administration sequence of PD-L1 immunotherapy and radiotherapy should be supplemented, whether concurrent administration or sequential application of immunotherapy and radiotherapy could achieve better efficacy should be described.</p></disp-quote><p>It is really true as Reviewer #2 suggested that whether concurrent administration or sequential application of immunotherapy and radiotherapy could achieve better efficacy. Data from mouse models have been obtained in support of various treatment schedules, encompassing radiotherapy immediately followed by ICIs, concomitant radiotherapy plus ICIs, as well as ICIs immediately followed by radiotherapy. The reason why we adopted immunotherapy induction administration was for preclinical research had reported that immunotherapy initiated before radiation has been shown to mediate superior therapeutic effects in mouse model.</p><p>References:</p><p>Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1. Immunotherapy + chemotherapy is the standard treatment recommended by current guidelines for high-risk triple-negative breast cancer. In this study, radiation therapy was administered to the primary breast lesion, and radiation therapy can cause an abscopal effect, so it is recommended to supplement the regression of lymph nodes in the node positive patients after radiation therapy and at the time of surgery.</p></disp-quote><p>As Reviewer #3 suggested, we have compared the regression of lymph nodes between baseline and after radiation therapy/at the time of surgery, respectively. There was no obvious regression in lymph nodes after radiation therapy, but all lymph nodes shrank to normal size at the time of surgery and confirmed pCR.</p><disp-quote content-type="editor-comment"><p>2. The relatively small sample size of this study is the major defect of this study, and further confirmatory studies are still needed.</p></disp-quote><p>Thank you for your good suggestion. It is really true as Reviewer #3 suggested that our study is a relatively small-scale trial. Further confirmation of these findings in a large-scale study is currently underway.</p></body></sub-article></article>